CSF2 and colorectal carcinoma: The study included heavily pretreated patients, with a median of 2 previous treatment lines.62 In the pooled analysis of the MSS CRC cohort of 2 PraG basket studies, the combination of radiotherapy and anti-PD-1 inhibitor and GM-CSF, the ORR was 25%, and the DCR 62.5%.66 Additionally, one of 9 treated patients had complete response.